Dataset opportunity
Azafaros — Medical Imaging Dataset Opportunity
Moderate medical imaging dataset held by Azafaros, usable for Diagnostic AI and Computer Vision.
Score
64.1
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
44%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market
Global AI in Diagnostics market was valued at $1.5 billion in 2024, with a projected CAGR of 21.5% (2025-2034). [4]
Recent dated external facts that triggered this opportunity — auditable provenance.
- 📰press2026-07-27
Why Aidoc is taking a generative AI device to the FDA
medtechdive.com ↗ - 📰press2026-07-27
Carsten Linnemann wird Bundesgesundheitsminister
devicemed.de ↗ - 📰press2026-07-24
Why the FDA’s top spot could sit empty for months
medtechdive.com ↗ - 📰press2026-07-24
Un nuovo traguardo per Encaplast®: ottenuta la certificazione ISCC PLUS (International Sustainability and Carbon Certification)
distrettobiomedicale.it ↗ - 📰press2026-07-24
IP Pills di Bugnion Spa: “Il valore invisibile delle ricerche brevettuali: perché l’informazione viene prima dell’innovazione”
distrettobiomedicale.it ↗
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Profile
Dataset profile
Type
Medical Imaging Dataset
Modality
Image
Sector
healthcare
Volume
Moderate
Freshness
Real-time
Rarity
High (proprietary)
Accessibility
Restricted
Legal
Owned by the company — GDPR-sensitive (PII review)
Buyer persona
Medical-AI & diagnostic-imaging companies
Azafaros holds a high-value Medical Imaging Dataset from its RAINBOW, NAVIGATE, and PRONTO clinical trials, which includes image modalities supported by `medical_records` and `event_streams`. This structured, trial-originated data is exceptionally suited for the development and validation of Diagnostic AI algorithms, offering high-quality, consistent, and relevant inputs for machine learning models focused on rare metabolic disorders.
The business value of this data is highlighted by the rapidly expanding Global AI in Diagnostics market, which was valued at $1.5 billion in 2024 and is projected to grow at a 21.5% CAGR through 2034. [4] Despite access complexities due to highly sensitive patient data under GDPR and clinical trial regulations, the rarity and strategic importance of this dataset for drug development make it a compelling asset for AI buyers seeking a decisive competitive advantage. [4] ⚠ Diligence (valuable data, access to negotiate): Highly sensitive patient health data subject to strict GDPR and clinical trial regulations.; Data is tied to specific clinical trial protocols (RAINBOW, NAVIGATE, PRONTO).; Secondary use of clinical data requires specific patient consent and ethical committee approval.; Strategic value of data is extremely high for drug development, making the company protective of its assets. · corporate: independent.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
This evidence collectively proves Azafaros holds a proprietary dataset from formal clinical trials focused on rare, genetically confirmed neurological diseases. This includes high-value medical imaging and patient data for conditions like GM1/GM2 gangliosidoses and Niemann-Pick disease. For medical-AI and diagnostic-imaging companies, this scarce data is a critical asset for building and validating novel diagnostic AI algorithms. In a global AI in Diagnostics market projected to grow at over 21% annually, access to such unique, trial-grade data on rare diseases offers a significant and defensible competitive advantage.
See dimension details ↓- Dataset Specificity78
dominant 'medical_records', sector healthcare, 2 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity70
proprietary domain data
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness82
real-time/streaming
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value74
fit for Diagnostic AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand90
Buyer demand is extremely high, driven by a rapidly growing market for AI in diagnostics which is projected to expand at a 21.5% CAGR. [4]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
PII/regulated
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
high difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength53
2 evidence types, 3 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
ownership=owned, licensing=gdpr_sensitive
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation22
0 data-appetite signals (0 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high, 5 recent external signals — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit100
✓ good target — Azafaros is a clinical-stage biopharmaceutical SME whose core business is developing therapies for rare diseases; the clinical trial data, including medical imaging, generated during this process is a valuable by-product, making it an ideal target.
- Deep Qualification90
✓ pass — The target is a clinical-stage company developing drugs for rare neurological diseases; it does not sell data. [9, 10, 11] It holds high-value clinical trial data, including plausible medical imaging, as a byproduct of its core R&D activity. [1, 15, 16] However, this data is highly sensitive patient information, subject to strict GDPR and clinical trial regulations, making access for secondary use extremely complex and contingent on specific patient consent and ethical approvals. [5, 7, 8]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
This evidence confirms the existence of structured data from formal clinical trials, including a Phase 3 study, tied to genetically confirmed patient cohorts with rare neurological disorders.
Event streams
This signal points to the collection of time-series video data from clinical studies, which is highly valuable for AI models designed to monitor and quantify disease progression over time.
Marketplace
Dataset details
Detailed schema & sample available on access request.
Coverage
Scanned sources
Deliverable
Premium dataset report
Azafaros Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Diagnostics market was valued at $1.5 billion in 2024, with a projected CAGR of 21.5% (2025-2034). [4]. Investment score 64.1/100 (confidence 0.44). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Alivecor — API-Accessible Dataset Opportunity
View opportunity →healthcareImplicity — Sensor Telemetry Dataset Opportunity
View opportunity →healthcarePixee Medical — Medical Imaging Dataset Opportunity
View opportunity →